Recently, an interest has developed in designing in biomaterials for medical ultrasonics that can provide the acoustic activity of microbubbles, but with improved stability in vivo and a smaller size distribution for extravascular interrogation. One proposed alternative is the phase-change contrast agent. Phase-change contrast agents (PCCAs) consist of perfluorocarbons (PFCs) that are initially in liquid form, but can then be vaporized with acoustic energy. Crucial parameters for PCCAs include their sensitivity to acoustic energy, their size distribution, and their stability, and this manuscript provides insight into the custom design of PCCAs for balancing these parameters. Specifically, the relationship between size, thermal stability and...
Phase-change contrast agents (PCCAs) provide a dynamic platform to approach problems in medical ultr...
Ultrasonically activated phase-change contrast agents (PCCAs) based on perfluorocarbon droplets have...
Ultrasonically activated phase-change contrast agents (PCCAs) based on perfluorocarbon droplets have...
Recently, an interest has developed in designing in biomaterials for medical ultrasonics that can pr...
Recent efforts using perfluorocarbon (PFC) nanoparticles in conjunction with acoustic droplet vapori...
Recent efforts using perfluorocarbon (PFC) nanoparticles in conjunction with acoustic droplet vapori...
Recent efforts using perfluorocarbon (PFC) nanoparticles in conjunction with acoustic droplet vapori...
Many studies have explored phase-change contrast agents (PCCAs) that can be vaporized by an ultrason...
Many studies have explored phase-change contrast agents (PCCAs) that can be vaporized by an ultrason...
Phase-change contrast agents (PCCAs) for ultrasound-based applications have resulted in novel ways o...
Phase-change contrast agents (PCCAs), which normally consist of nano/microscale droplets of liquid p...
Phase-change contrast agents (PCCAs) for ultrasound-based applications have resulted in novel ways o...
Phase-change contrast agents (PCCAs), which normally consist of nano/microscale droplets of liquid p...
In the past two decades, perfluorocarbon (PFC) droplets have been investigated for biomedical applic...
Phase-change contrast agents (PCCAs) provide a dynamic platform to approach problems in medical ultr...
Phase-change contrast agents (PCCAs) provide a dynamic platform to approach problems in medical ultr...
Ultrasonically activated phase-change contrast agents (PCCAs) based on perfluorocarbon droplets have...
Ultrasonically activated phase-change contrast agents (PCCAs) based on perfluorocarbon droplets have...
Recently, an interest has developed in designing in biomaterials for medical ultrasonics that can pr...
Recent efforts using perfluorocarbon (PFC) nanoparticles in conjunction with acoustic droplet vapori...
Recent efforts using perfluorocarbon (PFC) nanoparticles in conjunction with acoustic droplet vapori...
Recent efforts using perfluorocarbon (PFC) nanoparticles in conjunction with acoustic droplet vapori...
Many studies have explored phase-change contrast agents (PCCAs) that can be vaporized by an ultrason...
Many studies have explored phase-change contrast agents (PCCAs) that can be vaporized by an ultrason...
Phase-change contrast agents (PCCAs) for ultrasound-based applications have resulted in novel ways o...
Phase-change contrast agents (PCCAs), which normally consist of nano/microscale droplets of liquid p...
Phase-change contrast agents (PCCAs) for ultrasound-based applications have resulted in novel ways o...
Phase-change contrast agents (PCCAs), which normally consist of nano/microscale droplets of liquid p...
In the past two decades, perfluorocarbon (PFC) droplets have been investigated for biomedical applic...
Phase-change contrast agents (PCCAs) provide a dynamic platform to approach problems in medical ultr...
Phase-change contrast agents (PCCAs) provide a dynamic platform to approach problems in medical ultr...
Ultrasonically activated phase-change contrast agents (PCCAs) based on perfluorocarbon droplets have...
Ultrasonically activated phase-change contrast agents (PCCAs) based on perfluorocarbon droplets have...